share_log

Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(19.7%),OrbiMed Israel GP Ltd.(19.7%)

Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(19.7%),OrbiMed Israel GP Ltd.(19.7%)

美股SEC公告 ·  2023/01/05 16:31
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息